Menu
This is a summary.
Breast Cancer is the most frequently diagnosed cancer in the world. 12% of all cancers is breast cancer. One in 8 women will get breast cancer in her lifetime. More than 2 million new cases were diagnosed last year, most at stage 3 or later. 600,000 women died from the disease. Like covid widespread frequent screening is the key to reducing the deaths from breast cancer. Early detection reduces costs, suffering and deaths.
Pulmostics has developed a simple, painless fast breast cancer screening test. By identifying the volatile organic compounds found in the breath and urine of women we identify women who are likely to have breast cancer. Five minutes, no disrobing, no pain, and she is free to go.
SHARE:
Early detection is the key to reducing deaths from breast cancer. Yet most women are not screened for breast cancer. In the US 62% of women follow the recommended screening frequency. The rest of the world’s adherence is worse. In many countries less than 30% of women follow the recommended screening protocol. The absence of frequent screening results in 70% of breast cancer cases being diagnosed at stage 3 or later. Late state detection means higher treatment costs and poor outcomes.
Women do not get screened for a variety of reasons: availability, discomfort, cost, and access. The Mammogram is the gold standard for breast cancer screening. Mammogram centers are expensive and require highly skilled technicians and radiologists. Special shielded rooms must be built to protect the operators from the harm of radiation. In many countries there are not enough mammogram centers to screen women.
The mammogram is uncomfortable, sometimes even painful. This discomfort causes some women to defer their mammogram. The need to bare breasts, in contravention of social and religious traditions affects women’s adherence to screening protocol.
Pulmostics’ BreathSense™ 1000 removes many of the limitations and objections to screening. It is non-invasive, painless, affordable and can be administered at point of care – i.e., doctor’s office. One breath and five minutes is all it takes. No waiting hours or even days for results. Our system analyzes the patient’s breath and looks for a pattern of gasses in the breath that are characteristic of breast cancer.
Breath analysis has been demonstrated in small scale clinical trials to be able to detect breast cancer with a sensitivity and specificity that is like a mammogram. We are seeking funding to conduct a large-scale clinical trial (over 1000 women) to obtain the necessary clinical data for regulatory approvals. Regulatory approval is required before this rapid low-cost painless technology can be deployed in countries where it is needed.
Funds will be used to pay for the cost of a clinic trial in Mexico. The breakdown is the following:
Hospital charges 95,000
Testing instruments 60,000
Data collection 60,000
Clinical trial audit 100,000
Statistical Analysis 100,000
Outside laboratory services 85,000
We have contracted with Christus Muguerza hospitals in Monterey, Mexico to provide patients and facilities. We have recruited a talented oncologist associated with Christus Muguerza hospital as the primary investigator. The BreathSense™ 1000 is developed and we have the breath capture devices ready to go.
We have initiated discussions with investors and distribution partners. Discussions are underway with equity investors and other private charities to provide operating funding and clinical trial funds.
Breast cancer is the most frequently diagnosed cancer today. The number of breast cancer cases are increasing at an alarming rate. In some countries the rate of increase exceeds 2% per annum. In the absence of a screening technology that overcomes the current barriers: cost, pain and invasive x-rays, women will continue to not be screened. The death rate from breast cancer will continue its inexorable climb. This is unacceptable. If implemented at a global scale, we believe BreathSense™ 1000 could help save 500,000 women’s lives annually.
Mr. William Wittmeyer has 30+ year’s experience with technology companies. He successfully launched and led numerous technology companies through full life cycle from
start up to IPO. Mr. Wittmeyer has provided critical leadership and management to companies such as Exxon, WR Grace, Wittham, eXS, China Campus Wireless Networks and Electronic Sensor Technology. William holds a B.S. from the US Coast Guard Academy and an MBA from Columbia Graduate School of Business
Mr. Kramarz is a serial non-profit founder and tech entrepreneur, fractional CFO, angel investor and venture capitalist with a particular interest in the human side of business. Executive Director – Intelliversity – The Innovation Accelerator for the Real-World Board Chairman – Brain-Body Research Institute Executive Director – Jericho Center of Medical Diplomacy Venture Capital investor (Shepherd Ventures).
Chief Technology Officer
Dr. Jorge Leon is an internationally recognized expert and pioneer in the development and commercialization of clinical
molecular diagnostics. Dr. Leon has a PhD in Cellular and Molecular Biology from NYU and completed his post-doctoral
studies at the German Cancer Research Center in Heidelberg, Germany, and Columbia University in NYC. Dr. Leon played an
integral role in the founding and growing of the molecular diagnostics laboratories at Quest Diagnostics Incorporated. During his twelve-year tenure focused on building the Quest Diagnostic molecular menu and driving the molecular diagnostics strategy, which today is the largest molecular diagnostics service laboratory in the world with over 1.5 billion in revenues.
Chief Technology Officer
Dr. Yin Sun is the Chief Technology Officer of Pulmostics. He has been involved with the research and development of trace
chemical detection for over 23 years. He has significant experience in vapor and trace chemical detection including
instrumentation, data analysis and application development across medical, homeland security, food, and environmental applications. Dr. Sun has authored two highly recognized books on trace chemical detection and applications. Dr. Sun holds a PH.D. from the University of Connecticut.
Executive Vice President Mexico
Ms. Garcia is an accomplished business executive. Educated in the US and Mexico, fluent in five languages Ms. Garcia is a successful businesswoman on both sides of the border. Before engaging with Pulmostics to assist with business development in Mexico and Latin America, Ms. Garcia managed the Mexican subsidiary of a European luxury goods manufacturer and built a speciality retailer focusing on pet health.
Sign up for our newsletter. Receive updates about our latest campaigns and blogs, upcoming events, featured musical artists, and news and information about Music Beats Cancer.
Music Beats Cancer is a 501(c)(3) nonprofit organization. Tax ID #45-4642925
Music Beats Cancer is a 501(c)(3) nonprofit organization. Tax ID #45-4642925
$6503 donated by Anonymous
$1000 donated by Susan Tenney
$100 donated by Peter Olsen
$100 donated by Florin raica
$100 donated by farhad Mighani
$50 donated by Karen Siniscalco
$50 donated by Steve Friedman
$50 donated by Lalaine Braime
$50 donated by Lucas Root
$50 donated by Anonymous
$100 donated by rick barrera
$250 donated by Anonymous
$100 donated by Maxim Shapiro
$100 donated by ROBERT GOLDSTEIN
$75 donated by Florin raica
$50 donated by Robert Donnell
$150 donated by Florin raica
$100 donated by Robert Kramarz
$10000 donated by Anonymous
$100 donated by Linda Wohlsen
